Ribociclib for HR-Positive, Advanced Breast Cancer

被引：16
|
作者：
Araki, Kazuhiro [1 ]
Miyoshi, Yasuo [1 ]
机构：
[1] Hyogo Coll Med, Nishinomiya, Hyogo, Japan
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2017年 / 376卷 / 03期
关键词：
KINASE; 4/6; INHIBITOR; PALBOCICLIB; COMBINATION;
D O I：
10.1056/NEJMc1615255
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：288 / 288
页数：1
相关论文
共 50 条
  • [21] First-Line Therapy with Ribociclib plus Letrozole can prolong PFS in a wide Range of Patients with advanced HR-positive/HER2-negative Breast Cancer
    Dinkhoff, Karen
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (1-2) : 65 - 65
  • [22] Updates to the Management of HR-Positive, HER2-Negative Breast Cancer
    Gradishar, William J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22
  • [23] Efficacy of everolimus combined with endocrine therapy in HR-positive/HER-2-negative advanced breast cancer
    Song, Xifu
    Lu, Jingjing
    Wang, Liyan
    Kong, Feifei
    Yuan, Hangyu
    Chen, Cheng
    Shan, Haixia
    JOURNAL OF BUON, 2020, 25 (05): : 2228 - 2236
  • [24] CDK4/6 inhibitors in HR-positive breast cancer immunotherapy
    Shen, Mimi
    Ma, Zhiyuan
    Zhu, Jiaxing
    Wen, Guorong
    Jin, Hai
    An, Jiaxing
    Tuo, Biguang
    Liu, Xuemei
    Li, Taolang
    BIOORGANIC CHEMISTRY, 2025, 154
  • [25] Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer
    Ettl, Johannes
    BREAST CARE, 2016, 11 (03) : 174 - 176
  • [26] The CDK4/6 inhibitor in HR-positive advanced breast cancer: A systematic review and meta-analysis
    Ding, Wu
    Li, Zhian
    Wang, Caiyun
    Ruan, GuoDong
    Chen, LuPing
    Tu, Chuanjian
    MEDICINE, 2018, 97 (20)
  • [27] Overview of the relevance of PI3K pathway in HR-positive breast cancer
    Vasan, N.
    Toska, E.
    Scaltriti, M.
    ANNALS OF ONCOLOGY, 2019, 30 : 3 - 11
  • [28] Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Buyukkaramikli, Nasuh C.
    de Groot, Saskia
    Riemsma, Rob
    Fayter, Debra
    Armstrong, Nigel
    Portegijs, Piet
    Duffy, Steven
    Kleijnen, Jos
    Al, Maiwenn J.
    PHARMACOECONOMICS, 2019, 37 (02) : 141 - 153
  • [29] Exemestane plus entinostat in HR-positive/HER2-negative breast cancer?
    Lichert, Frank
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (01) : 18 - 18
  • [30] Systemic Therapy of HR-positive, HER2-negative metastatic Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (03) : 257 - 257
12345